Research activities in the Immunology-Oncology Axis focus on the study of cancer, particularly hematological cancers. An understanding of mechanisms that regulate genomic instability, cancer development, immune reconstitution and T cell response will lead to new approaches in cellular and molecular therapy to treat hematological diseases and improve the success rates of hematopoietic stem cell transplantation. Clinical research in this area is extremely active, and our clinician researchers in hematology and oncology have achieved major advances.
For example, this expertise has led to the creation of a Centre of Excellence for Cellular Therapy (CECT), a unique group of laboratories in Canada that perform research on hematopoietic stem cells, the immune system, and cancer. As a further boost to the development of new technologies, researchers from this axis have received two major grants from the Networks of Centres of Excellence, which have led to the creation of the Centre for Commercialisation of Cancer Immunotherapy (C3i) and the Regenerative Medicine and Cell Therapy Network (CellCAN).
This strength in fundamental, translational and clinical research is also demonstrated through our researchers’ contributions to many major projects carried out a mari usque ad mare, such as the Québec Cell, Tissue and Gene Therapy Network (Thécell Network) of the FRQS, the Stem Cell Network and the Canadian Donation and Transplantation Research Program.
Many of these researchers collaborate with the Institute for Research in Immunology and Cancer (IRIC) at Université de Montréal.